Title
Category
Credits
Event date
Cost
  • PAINWeek
  • 11.00 AANP
  • 11.00 ACCME (All Other)
  • 11.00 ACCME (MD/DO Only)
  • 11.00 ACPE Pharmacy
  • 11.00 ANCC
  • 11.00 APA
$1,500.00
  • 15.25 AANP
  • 15.25 ACCME (All Other)
  • 15.25 ACCME (MD/DO Only)
  • 15.25 ACPE Pharmacy
  • 15.25 ANCC
  • 15.00 APA
$1,500.00
  • PAINWeek
  • 20.00 AANP
  • 20.00 ACCME (All Other)
  • 20.00 ACCME (MD/DO Only)
  • 20.00 ACPE Pharmacy
  • 20.00 ANCC
  • 20.00 APA
$1,500.00
  • PAINWeek
  • 22.00 AAFP
  • 22.00 AANP
  • 22.00 ACCME (All Other)
  • 22.00 ACCME (MD/DO Only)
  • 22.00 ACPE Pharmacy
  • 22.00 ANCC
  • 22.00 APA
$499.00
The enormity of CNS-related conditions poses an immense burden to public health. In 2022, there remain significant knowledge gaps among clinicians treating neurologic and psychiatric disorders. Conditions such as dementia, epilepsy, migraine, MS, and stroke require a more inclusive approach to continuing medical education.The BRAINWeek 2022 Digital All Access agenda has been crafted to address the most frequently diagnosed conditions encountered in clinical practice, with an emphasis on collaborative care among specialists and frontline practitioners. 
  • LivDerm
  • TME
  • 1.75 AAPA Category I CME
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
  • LivDerm
  • TME
  • 0.25 AMA PRA Category 1 Credit
  • 0.25 ANCC
  • 0.25 Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this activity, experts will discuss the recent advances with nonsteroidal MRAs in patients with type 2 diabetes and CKD, as well as their potential application to patient care.
  • CMHC
  • TME
$0.00
The increasing prevalence and impacts of overweight and obesity in patients with type 2 diabetes renders weight loss and weight loss maintenance an important part of treatment goals. In this 6-part webcast series, chaired by Robert H. Eckel, MD and Donna Ryan, MD, you will have a chance to hear from experts on the comprehensive management of obesity in patients with type 2 diabetes, including lifestyle modifications, the spectrum of pharmacotherapy and metabolic surgery, as well as how to practically apply these concepts to patient care.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is a common condition in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) that can affect quality of life and lead to suboptimal outcomes. Despite the impacts of IDA in NDD-CKD patients, its screening, diagnosis, and treatment remains challenging. Recent trials and evidence has shown that i.v. iron supplementation for the treatment of IDA might be beneficial in this setting, and during this webcast,, experts will discuss important advances and considerations about the screening, diagnosis, and treatment of IDA in patients with NDD-CKD.

Pages